Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
Randomized Controlled Trial
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
In a recent large phase III study, previously treated patients with advanced non-small cell lung cancer who received pemetrexed demonstrated a survival time similar to patients who received docetaxel (median, 8.3 months with pemetrexed versus 7.9 months with docetaxel), with a more favorable toxicity profile, and significantly fewer Common Toxicity Criteria grade 3/4 toxicities. This is a retrospective risk-benefit analysis of survival without grade 3/4 toxicity, defined as the time to the first occurrence of Common Toxicity Criteria grade 3 or 4 toxicity or death, in the prospective phase III study comparing pemetrexed with docetaxel. ⋯ This analysis of survival without grade 3/4 toxicity suggests a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of patients with non-small cell lung cancer.
-
Primary liposarcomas of the mediastinum are extremely rare neoplasms, comprising less than 1% of all mediastinal tumors. These tumors occur most commonly in the lower extremities (75%) and less frequently in the retroperitoneum. We present a case involving a successful radical resection of a large myxoid liposarcoma and its recurrence, both located in the posterior mediastinum.